Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis ...Middle East

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of disability progression versus those who switched later from teriflunomide to Kesimpta1...

Hence then, the article about novartis presents new five year data on disability outcomes and safety of kesimpta ofatumumab in people living with relapsing multiple sclerosis was published today ( Thursday 20/04/2023 - 08:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis )

Also on site :

• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• “The Nation” Nominates Minneapolis for the Nobel Peace Prize
• R&B Legend's Global Tour With Akon Announced